About this trial
This research makes several significant contributions to the field of BrS. It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis. The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndrome's molecular mechanisms, facilitating targeted therapies and refined risk stratification. These advancements optimize patient care by enabling personalized treatment plans and risk assessment. Overall, this research adds value by advancing diagnostic methods, providing molecular insights, optimizing patient care, and positively impacting public health outcomes in BrS.
Eligibility criteria
Qualifiers
Age > 18 years
Patients affected by Brugada Syndrome
Patients who signs the Informed Consent
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
IRCCS Policlinico S. Donato
Lead sponsor
Azienda Ospedaliero Universitaria di Sassari
Collaborator
The National Research Council, Italy
Collaborator